Biophytis s'introduit sur Alternext Paris


Raises €10 million, market capitalisation €32.7 million

Paris – 16 July  2015– EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for small and medium-sized companies (SMEs),today celebrated the listing of Biophytis, a French company that develops drugs to treat degenerative illnesses associated with aging. Biophytis is listed on Alternext in Paris. 

Biophytis is a biotechnology company founded in 2006. It develops first-in-class drugs to treat degenerative illnesses associated with aging for which there is currently no treatment. Its two most advanced programmes, BIO101 and BIO201, relate to sarcopenia (loss of muscle function) and age-related macular degeneration (ARMD), respectively.

The company is looking to sign its first licensing agreement in 2017 with internationally known pharmaceutical companies.

Biophytis (ticker code: ALBPS) was listed through the admission to trading on 13 July 2015 of 5,442,135 ordinary shares making up its equity, including 1,672,500 new shares issued through a Global Offering[1].

The admission and issue price of Biophytis shares was set at €6.00 per share. Market capitalisation was €32.7 million on the day of listing, and the total amount raised was €10 million.

Stanislas Veillet, Chairman and CEO of Biophytis said: “We are very proud to list on Alternext. The funds raised will go to accelerate the clinical development of our drug candidates for treating sarcopenia and ARMD. Both of these age-related illnesses, for which there is currently no treatment, are scourges of the 21st century given the general aging of our population.”

Eric Forest, CEO of EnterNext, said:“We are delighted to welcome Biophytis, a Paris region biotech company, to Alternext. We have worked with many biotech businesses as they look to financial markets for the capital they need to step up their growth. Listing will give Biophytis the resources it needs to start up its clinical trials and will also raise its profile on international markets. This is the first European company to list on Alternext that specialises in degenerative illnesses. Biophytis is also the 25th mid-size company to make its market debut with us this year. Listings have taken off since the beginning of 2015, and we are confident that this company will trigger interest from investors.”

To celebrate Biophytis’s listing, Stanislas Veillet presented two  €2,500 cheques to the “Institut de Myologie” and the “Voir et Entendre” Foundation, not-for-profits dedicated to patient care.

[1]The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.


Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter ( and LinkedIn (

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

© 2023, Euronext N.V. - All rights reserved.